Phase II Study of Safusidenib Erbumine in Patients with Chemotherapy- and Radiotherapy-Naïve Isocitrate Dehydrogenase 1-Mutated WHO Grade 2 Gliomas
November 2025
in “
Neuro-Oncology
”
Studysummary In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →